FDA's Brilliant Management of Avandia Re-Review Provides Flexibility on Final Decision
This article was originally published in RPM Report
Executive Summary
Going into the Avandia re-review, FDA looked stuck between a rock and a hard place. Coming out of the FDA advisory committee meeting, the agency has a full set of options to choose from that would likely be viewed as a credible outcome by the public. But possible surprises remain.
You may also be interested in...
FDA Using Medicare Data Linked to NCI Databases to Look at Cancer Signals
FDA is looking at linking Medicare data to National Cancer Institute registries to enhance the information from medical claims data and gain a better understanding of disease-cancer and drug-cancer relationships. A familiar figure from FDA epidemiological work is keenly involved: safety officer David Graham.
FDA’s Go-To Statistician: UW’s Fleming Holds Court At Xifaxan Advisory Committee Meeting
University of Washington statistician Thomas Fleming seems to be showing up more often on FDA advisory committees and is having an outsized impact on the meetings.
Bristol-Myers Squibb/AstraZeneca Onglyza is Guinea Pig for FDA Mini-Sentinel Post-Market Surveillance
FDA’s Congressionally-mandated active surveillance system, Sentinel, is ready for shakedown cruises in 2011. One of the first projects will be a close examination of real-world experience and cardiovascular events associated with saxagliptin. That’s a dubious distinction for BMS/AZ, the co-marketers of Onglyza–but it also sets up a new dynamic that all sponsors should watch.